Drug Profile
SR 121566
Alternative Names: SR 121566ALatest Information Update: 29 Nov 2001
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis